BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32370480)

  • 21. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography].
    Faber L; Seggewiss H; Fassbender D; Bogunovic N; Strick S; Schmidt HK; Gleichmann U
    Z Kardiol; 1998 Mar; 87(3):191-201. PubMed ID: 9586154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.
    Kuhn H; Lawrenz T; Lieder F; Leuner C; Strunk-Mueller C; Obergassel L; Bartelsmeier M; Stellbrink C
    Clin Res Cardiol; 2008 Apr; 97(4):234-43. PubMed ID: 18071624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percutaneous transluminal septal myocardial ablation: past, present, and future.
    Maekawa Y; Takamisawa I; Takano H; Takayama M
    J Cardiol; 2022 Sep; 80(3):211-217. PubMed ID: 34924238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Faber L; Gleichmann U
    Thorac Cardiovasc Surg; 1999 Apr; 47(2):94-100. PubMed ID: 10363608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is There a Role for Alcohol Septal Ablation in Young Patients with Medically Refractory Hypertrophic Obstructive Cardiomyopathy?
    Sivakumar K; Jain G
    Pediatr Cardiol; 2024 Mar; 45(3):648-659. PubMed ID: 36995405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.
    Faber L; Meissner A; Ziemssen P; Seggewiss H
    Heart; 2000 Mar; 83(3):326-31. PubMed ID: 10677415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful percutaneous transluminal septal myocardial ablation through a right superior septal artery for a patient with hypertrophic obstructive cardiomyopathy.
    Kurita T; Tsuchikane E; Tanaka N; Suzuki T
    Cardiovasc Interv Ther; 2015 Oct; 30(4):377-81. PubMed ID: 25502014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy.
    Cavigli L; Fumagalli C; Maurizi N; Rossi A; Arretini A; Targetti M; Passantino S; Girolami F; Tomberli B; Baldini K; Tomberli A; Antoniucci D; Yacoub MH; Marchionni N; Stefano PL; Cecchi F; Olivotto I
    Int J Cardiol; 2018 Dec; 273():155-161. PubMed ID: 30213605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Significance of Initial r-Wave in Leads V1 and aVR Before PTSMA in Patients with Hypertrophic Obstructive Cardiomyopathy.
    Jiang X; Qiao S
    Int J Gen Med; 2021; 14():9589-9598. PubMed ID: 34916839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of long-term outcome after septal myectomy in symptomatic hypertrophic obstructive cardiomyopathy patients with previous alcohol septal ablation and residual obstruction.
    Zhu C; Tang B; Cui H; Wang S; Xiao M; Chen Z; Meng Y; Zhao S; Song Y; Yu Q; Wang S
    J Card Surg; 2019 Jul; 34(7):533-540. PubMed ID: 31111576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MR imaging evaluation of regional, remote, and global effects of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Amano Y; Takayama M; Kumita S; Kumazaki T
    J Comput Assist Tomogr; 2007; 31(4):600-4. PubMed ID: 17882040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Role of cardiac magnetic resonance on predicting outcome in patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous transluminal septal myocardial ablation].
    Du H; Lu M; Yin G; Yin X; Jiang Y; Wang J; Chen X; Song L; Huang J; Zhang Y; Zhao S
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Aug; 42(8):665-9. PubMed ID: 25388340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.
    Malek LA; Chojnowska L; Klopotowski M; Maczynska R; Demkow M; Witkowski A; Kusmierczyk B; Piotrowicz E; Konka M; Dabrowski M; Ruzyllo W
    Eur J Heart Fail; 2008 Nov; 10(11):1123-6. PubMed ID: 18840395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy through non-left anterior descending septal perforators.
    Imori Y; Takano H; Kitamura M; Aoyama R; Sangen H; Kenta O; Matsuda J; Kubota Y; Tokita Y; Yamamoto T; Asai K; Takayama M; Shimizu W
    Heart Vessels; 2020 May; 35(5):647-654. PubMed ID: 31641886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic resonance imaging of microvascular obstruction in hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation.
    Amano Y; Kitamura M; Yamada F; Aita K; Takayama M; Tachi M; Kumita S
    Acta Radiol; 2015 Nov; 56(11):1323-8. PubMed ID: 25414371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Non-drug treatment for hypertrophic obstructive cardiomyopathy in children].
    Zhang X; Li YF; Xie B; Chen JY; Qian MY
    Zhonghua Er Ke Za Zhi; 2011 May; 49(5):381-5. PubMed ID: 21624293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy.
    Arslan F; Akdim F; Ten Berg JM
    Catheter Cardiovasc Interv; 2021 Feb; 97(3):488-492. PubMed ID: 32808736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does ablation of atrial fibrillation at the time of septal myectomy improve survival of patients with obstructive hypertrophic cardiomyopathy?
    Cui H; Schaff HV; Dearani JA; Lahr BD; Viehman JK; Geske JB; Nishimura RA; Ommen SR
    J Thorac Cardiovasc Surg; 2021 Mar; 161(3):997-1006.e3. PubMed ID: 32977972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Myocardial perfusion evaluation post percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy by ⁹⁹Tc(m) MIBI SPECT MPI].
    Sun XX; Tian YQ; Qiao SB; Yuan JS; Duan FJ; Wang DY; Guo F; He ZX
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jun; 39(6):497-502. PubMed ID: 21924073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.